The combination treatment of metformin and pemetrexed exerted an additive antiproliferative effect in three NSCLC cell lines we used with either wild type epidermal growth factor receptor (EGFR; A549) or mutant type EGFR (H1975 and HCC827). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.